Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
New Era of Preventing End-Stage Kidney Disease Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
New Era of Preventing End-Stage Kidney Disease Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 · third_quarter · Q3
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Source: Senate LDA
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
New Era of Preventing End-Stage Kidney Disease Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Safe Step Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Safe Step Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Safe Step Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Safe Step Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act, concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
EPIC Act of 2025
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Appropriations for the Department of Health & Human Services and the Department of Veterans Affairs, and Department of Defense.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 · second_quarter · Q2
Appropriations for the Department of Health & Human Services and the Department of Veterans Affairs, and Department of Defense.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 · first_quarter · Q1
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Appropriations for the Department of Health & Human Services, the Department of Veterans Affairs, and the Department of Defense.
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2025 · fourth_quarter · Q4
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act, relating to pharmaceuticals.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act, concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE